These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 36535992)

  • 1. Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.
    Jones G; Arias D; Nock M
    Sci Rep; 2022 Dec; 12(1):21927. PubMed ID: 36535992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.
    Jones G; Lipson J; Wang E
    Sci Rep; 2023 Feb; 13(1):2466. PubMed ID: 36774449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes.
    Jones GM
    J Psychopharmacol; 2023 Jan; 37(1):61-69. PubMed ID: 36314881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between classic psychedelics and nicotine dependence in a nationally representative sample.
    Jones G; Lipson J; Nock MK
    Sci Rep; 2022 Jun; 12(1):10578. PubMed ID: 35732796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.
    Jones G; Ricard JA; Lipson J; Nock MK
    Sci Rep; 2022 Apr; 12(1):4099. PubMed ID: 35393455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study.
    Jones GM; Nock MK
    Sci Rep; 2022 Feb; 12(1):2574. PubMed ID: 35173246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.
    Jones GM; Nock MK
    Sci Rep; 2022 Oct; 12(1):16976. PubMed ID: 36216840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):66-73. PubMed ID: 35090364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between naturalistic use of psychedelics and co-occurring substance use disorders.
    Rabinowitz J; Lev-Ran S; Gross R
    Front Psychiatry; 2022; 13():1066369. PubMed ID: 36704738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease.
    Tagen M; Mantuani D; van Heerden L; Holstein A; Klumpers LE; Knowles R
    J Psychopharmacol; 2023 Sep; 37(9):876-890. PubMed ID: 37572027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing Psychedelics and MDMA.
    Liechti ME; Holze F
    Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus.
    Cuomo MJ; Dyment PG; Gammino VM
    J Am Coll Health; 1994 May; 42(6):271-4. PubMed ID: 7913938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults.
    Yang KH; Han BH; Palamar JJ
    Addict Behav; 2022 Sep; 132():107343. PubMed ID: 35525189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-drug interactions involving classic psychedelics: A systematic review.
    Halman A; Kong G; Sarris J; Perkins D
    J Psychopharmacol; 2024 Jan; 38(1):3-18. PubMed ID: 37982394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.